Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,855 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recovery from prolonged thrombocytopenia in patients with TAFRO syndrome: case series and literature review.
Yamaguchi Y, Maeda Y, Shibahara T, Nameki S, Nakabayashi A, Komuta K, Mizuno Y, Yagita M, Manabe Y, Morita T, Nishide M, Watanabe A, Takamatsu H, Nishida S, Hirano T, Shima Y, Narazaki M, Kumanogoh A. Yamaguchi Y, et al. Among authors: nishida s. Mod Rheumatol Case Rep. 2020 Jul;4(2):302-309. doi: 10.1080/24725625.2020.1717747. Epub 2020 Feb 3. Mod Rheumatol Case Rep. 2020. PMID: 33087016 Review.
Wilms tumour 1 peptide vaccine as a cure-oriented post-chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse.
Nakata J, Nakae Y, Kawakami M, Morimoto S, Motooka D, Hosen N, Fujiki F, Nakajima H, Hasegawa K, Nishida S, Tsuboi A, Oji Y, Oka Y, Kumanogoh A, Sugiyama H. Nakata J, et al. Among authors: nishida s. Br J Haematol. 2018 Jul;182(2):287-290. doi: 10.1111/bjh.14768. Epub 2017 May 23. Br J Haematol. 2018. PMID: 28542830 Free article. Clinical Trial. No abstract available.
Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study.
Shiroyama T, Nagatomo I, Koyama S, Hirata H, Nishida S, Miyake K, Fukushima K, Shirai Y, Mitsui Y, Takata S, Masuhiro K, Yaga M, Iwahori K, Takeda Y, Kida H, Kumanogoh A. Shiroyama T, et al. Among authors: nishida s. Sci Rep. 2019 Feb 21;9(1):2447. doi: 10.1038/s41598-019-39120-6. Sci Rep. 2019. PMID: 30792455 Free PMC article.
Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments.
Nishida S, Tsuboi A, Tanemura A, Ito T, Nakajima H, Shirakata T, Morimoto S, Fujiki F, Hosen N, Oji Y, Kumanogoh A, Kawase I, Oka Y, Azuma I, Morita S, Sugiyama H. Nishida S, et al. Medicine (Baltimore). 2019 Aug;98(33):e16771. doi: 10.1097/MD.0000000000016771. Medicine (Baltimore). 2019. PMID: 31415377 Free PMC article. Clinical Trial.
CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study.
Otsuka T, Nishida S, Shibahara T, Temizoz B, Hamaguchi M, Shiroyama T, Kimura K, Miyake K, Hirata H, Mizuno Y, Yagita M, Manabe Y, Kuroda E, Takeda Y, Kida H, Ishii KJ, Kumanogoh A. Otsuka T, et al. Among authors: nishida s. BMC Cancer. 2022 Jul 7;22(1):744. doi: 10.1186/s12885-022-09818-4. BMC Cancer. 2022. PMID: 35799134 Free PMC article. Clinical Trial.
1,855 results